

Product Datasheet

Bmf Antibody - BSA Free NBP1-76658

Unit Size: 0.1 mg

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Publications: 2

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP1-76658

Updated 9/9/2025 v.20.1

Earn rewards for product
reviews and publications.

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NBP1-76658



NBP1-76658

Bmf Antibody - BSA Free


| Product Information | |
|-------------------------|--|
| Unit Size | 0.1 mg |
| Concentration | 1 mg/ml |
| Storage | Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. |
| Clonality | Polyclonal |
| Preservative | 0.02% Sodium Azide |
| Isotype | IgG |
| Purity | Peptide affinity purified |
| Buffer | PBS |
| Target Molecular Weight | 22 kDa |

| Product Description | |
|---------------------|---|
| Description | Novus Biologicals Rabbit Bmf Antibody - BSA Free (NBP1-76658) is a polyclonal antibody validated for use in WB, ELISA and ICC/IF. Anti-Bmf Antibody: Cited in 2 publications. All Novus Biologicals antibodies are covered by our 100% guarantee. |
| Host | Rabbit |
| Gene ID | 90427 |
| Gene Symbol | BMF |
| Species | Human, Mouse |
| Immunogen | Antibody was raised with a synthetic peptide corresponding to 15 amino acids near the amino terminus of human Bmf. The immunogen is located within the first 50 amino acids of Bmf. Amino Acid Sequence: EPSQCVEELEDV |


| Product Application Details | |
|-----------------------------|--|
| Applications | Western Blot, ELISA, Immunocytochemistry/ Immunofluorescence |
| Recommended Dilutions | Western Blot 1-2 ug/ml, ELISA 1:100-1:2000, Immunocytochemistry/ Immunofluorescence 5-10 ug/ml |

Images


Western Blot: Bmf Antibody - BSA Free [NBP1-76658] - Bmf Antibody [NBP1-76658] - Identification of target for LPS-induced miR-29b in OCs. BMMs were incubated with M-CSF (30 ng/ml) and RANKL (40 ng/ml) for 40 h, washed thoroughly, and incubated further with LPS (50 ng/ml) in the presence of M-CSF (30 ng/ml) for 48 h. Cells were transfected with 30 nM of miR-29b mimic or con mimic in the presence of M-CSF (30 ng/ml) for 6 h. Total RNA was analyzed by qPCR to quantify the expression of BMF, PUMA, BAK1, BIM, and HRK. Expression levels with con mimic treatment were set at 1. Cell lysates were subjected to Western blot analysis with antibodies against BMF, PUMA, BAK1, BIM, HRK, and BCL-2. Antibodies against beta-actin were used for normalization. Image collected and cropped by CiteAb from the following publication (<https://www.hindawi.com/journals/omcl/2019/6018180/>) licensed under a CC-BY license.




Western Blot: Bmf Antibody [NBP1-76658] - Analysis of Bmf in 293 cell lysate with Bmf antibody at (A) 1 and (B) 2 ug/ml.




Western Blot: Bmf Antibody - BSA Free [NBP1-76658] - Identification of target for LPS-induced miR-29b in OCs. BMMs incubated w/ M-CSF (30 ng/ml) & RANKL (40 ng/ml) for 40 h, washed thoroughly, & incubated further w/ LPS (50 ng/ml) in presence of M-CSF (30 ng/ml) for 48 h. (a) Cells transfected w/ 30 nM of miR-29b mimic or con mimic in presence of M-CSF (30 ng/ml) for 6 h. Total RNA analyzed by qPCR to quantify the expression of BMF, PUMA, BAK1, BIM, & HRK. Expression levels w/ con mimic treatment set at 1. Cell lysates subjected to WB analysis w/ antibodies against BMF, PUMA, BAK1, BIM, HRK, & BCL-2. Antibodies against β -actin used for normalization. (b) w/out transfection, total RNA analyzed by qPCR to quantify the expression of BMF, & cell lysates subjected to WB analysis w/ anti-BMF Ab. (c) Total RNA & tissue lysate of tibiae from LPS-treated or vehicle-treated (V, PBS) mice analyzed by qPCR to quantify the expression of BMF & subjected to WB analysis w/ antibodies against BMF. (d) Cells thoroughly washed, transfected w/ 30 nM of anti-miR-29b or con inh, & stimulated w/ LPS (50 ng/ml) in presence of M-CSF. After 48 h, total RNA analyzed by qPCR to quantify BMF expression. Expression levels w/ con inh treatment set at 1.0. Cell lysates subjected to WB analysis w/ anti-BMF & anti-BCL-2 Ab. (e) Cells thoroughly washed, transfected w/ 50 nM of scRNA or siBMF, stimulated w/ LPS (50 ng/ml) in presence of M-CSF for 48 h, & analyzed to measure TRAP-positive MNCs & annexin V-positive cells. siRNA-mediated silencing of BMF confirmed by RT-PCR & qPCR. The Ct values of genes widely distributed between 17.33 & 30.92. \square $p < 0.05$; $\square\square$ $p < 0.01$; $\square\square\square$ $p < 0.001$ compared w/ each corresponding control. Similar results obtained from 3 independent experiments. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/31093317>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: Bmf Antibody - BSA Free [NBP1-76658] - Identification of target for LPS-induced miR-29b in OCs. BMMs incubated w/ M-CSF (30 ng/ml) & RANKL (40 ng/ml) for 40 h, washed thoroughly, & incubated further w/ LPS (50 ng/ml) in presence of M-CSF (30 ng/ml) for 48 h. (a) Cells transfected w/ 30 nM of miR-29b mimic or con mimic in presence of M-CSF (30 ng/ml) for 6 h. Total RNA analyzed by qPCR to quantify the expression of BMF, PUMA, BAK1, BIM, & HRK. Expression levels w/ con mimic treatment set at 1. Cell lysates subjected to WB analysis w/ antibodies against BMF, PUMA, BAK1, BIM, HRK, & BCL-2. Antibodies against β -actin used for normalization. (b) w/out transfection, total RNA analyzed by qPCR to quantify the expression of BMF, & cell lysates subjected to WB analysis w/ anti-BMF Ab. (c) Total RNA & tissue lysate of tibiae from LPS-treated or vehicle-treated (V, PBS) mice analyzed by qPCR to quantify the expression of BMF & subjected to WB analysis w/ antibodies against BMF. (d) Cells thoroughly washed, transfected w/ 30 nM of anti-miR-29b or con inh, & stimulated w/ LPS (50 ng/ml) in presence of M-CSF. After 48 h, total RNA analyzed by qPCR to quantify BMF expression. Expression levels w/ con inh treatment set at 1.0. Cell lysates subjected to WB analysis w/ anti-BMF & anti-BCL-2 Ab. (e) Cells thoroughly washed, transfected w/ 50 nM of scrRNA or siBMF, stimulated w/ LPS (50 ng/ml) in presence of M-CSF for 48 h, & analyzed to measure TRAP-positive MNCs & annexin V-positive cells. siRNA-mediated silencing of BMF confirmed by RT-PCR & qPCR. The Ct values of genes widely distributed between 17.33 & 30.92. \square $p < 0.05$; $\square\square$ $p < 0.01$; $\square\square\square$ $p < 0.001$ compared w/ each corresponding control. Similar results obtained from 3 independent experiments. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/31093317>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




Western Blot: Bmf Antibody - BSA Free [NBP1-76658] - Identification of target for LPS-induced miR-29b in OCs. BMMs incubated w/ M-CSF (30 ng/ml) & RANKL (40 ng/ml) for 40 h, washed thoroughly, & incubated further w/ LPS (50 ng/ml) in presence of M-CSF (30 ng/ml) for 48 h. (a) Cells transfected w/ 30 nM of miR-29b mimic or con mimic in presence of M-CSF (30 ng/ml) for 6 h. Total RNA analyzed by qPCR to quantify the expression of BMF, PUMA, BAK1, BIM, & HRK. Expression levels w/ con mimic treatment set at 1. Cell lysates subjected to WB analysis w/ antibodies against BMF, PUMA, BAK1, BIM, HRK, & BCL-2. Antibodies against β -actin used for normalization. (b) w/out transfection, total RNA analyzed by qPCR to quantify the expression of BMF, & cell lysates subjected to WB analysis w/ anti-BMF Ab. (c) Total RNA & tissue lysate of tibiae from LPS-treated or vehicle-treated (V, PBS) mice analyzed by qPCR to quantify the expression of BMF & subjected to WB analysis w/ antibodies against BMF. (d) Cells thoroughly washed, transfected w/ 30 nM of anti-miR-29b or con inh, & stimulated w/ LPS (50 ng/ml) in presence of M-CSF. After 48 h, total RNA analyzed by qPCR to quantify BMF expression. Expression levels w/ con inh treatment set at 1.0. Cell lysates subjected to WB analysis w/ anti-BMF & anti-BCL-2 Ab. (e) Cells thoroughly washed, transfected w/ 50 nM of scrRNA or siBMF, stimulated w/ LPS (50 ng/ml) in presence of M-CSF for 48 h, & analyzed to measure TRAP-positive MNCs & annexin V-positive cells. siRNA-mediated silencing of BMF confirmed by RT-PCR & qPCR. The Ct values of genes widely distributed between 17.33 & 30.92. \square $p < 0.05$; $\square\square$ $p < 0.01$; $\square\square\square$ $p < 0.001$ compared w/ each corresponding control. Similar results obtained from 3 independent experiments. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/31093317>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




Immunocytochemistry/ Immunofluorescence: Bmf Antibody - BSA Free [NBP1-76658] - Immunofluorescence of Bmf in HeLa cells with Bmf antibody at 5 ug/mL.

Red: Bmf Antibody
Blue: DAPI staining



Immunocytochemistry/ Immunofluorescence: Bmf Antibody - BSA Free [NBP1-76658] - Immunocytochemistry of Bmf in HeLa cells with Bmf antibody at 10 ug/mL.



Publications

Popescu B, Stahlhut C, Tarver TC et al. Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML Cell reports. *Medicine* 2023-11-21 [PMID: 37992684]

Sul O. J, Rajasekaran M, et al. MicroRNA-29b Enhances Osteoclast Survival by Targeting BCL-2-Modifying Factor after Lipopolysaccharide Stimulation. *Oxid Med Cell Longev* 2019-05-17 [PMID: 31093317] (WB, Mouse)



Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NBP1-76658

| | |
|---------------|---|
| NBP1-76658PEP | Bmf Antibody Blocking Peptide |
| NBP2-33376H | Blue Marker Antibody (6F4-F6) [HRP] |
| HAF008 | Goat anti-Rabbit IgG Secondary Antibody [HRP] |
| NB7160 | Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] |
| NBP2-24891 | Rabbit IgG Isotype Control |

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP1-76658

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

